Clinical trials: Alpha-Synucleinopathy
Dementia With Lewy Bodies (DLB)
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB.
- Trial name
- AscenD-LB (NCT04001517)
- Testing
- Neflamapimod
- Where
- 24 sites in United States, Netherlands
- Volunteers
- 91 people
- Sponsor
- EIP Pharma Inc
Dementia With Lewy Bodies
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB.
- Trial name
- NCT05869669
- Testing
- Neflamapimod
- Where
- 40 sites in United States, Netherlands and 1 more
- Volunteers
- 159 people
- Sponsor
- EIP Pharma Inc
Parkinson's Disease
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
The primary objective of the study is to evaluate the clinical efficacy of BIIB054 via dose response using the change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score.
- Trial name
- SPARK (NCT03318523)
- Testing
- BIIB054
- Where
- 75 sites in United States, Austria and 7 more
- Volunteers
- 357 people
- Sponsor
- Biogen
Parkinson Disease, Parkinsonian Disorders
Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.
- Trial name
- NCT01380899
- Testing
- Biopsy of skin
- Where
- Mexico
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí